quantification of accumulation of amyloid plaques in the brain over a long period of time (typically several years), measured by using PET scan imaging technology. The accumulation of amyloid plaques can be a biomarker for Alzheimer's disease
amyloid-beta measurement +
beta-secretase 1 measurement
caudate nucleus volume +
cerebral amyloid deposition measurement
diffuse plaque measurement
family history of Alzheimer’s disease
glucose metabolism decline measurement
left inferior lateral ventricle volume measurement
neuritic plaque measurement
p-tau measurement
p-tau:beta-amyloid 1-42 ratio measurement
PHF-tau measurement
soluble triggering receptor expressed on myeloid cells 2 measurement